VC-backed technology company developing disruptive technologies to boost recombinant biologics production using proprietary technologies based on Baculovirus vector expression systems (BVES) in insect cells.
Supported by a first in class Strategic Advisory Board combining investment and operational experience in developing companies in animal and human health.
Two proprietary and patented technology platforms, Top-Bac® and CrisBio®, to respond to industryâ€™s challenges in the production of biologicals: development time, scalability, versatility and cost.
Data available in various protein classes and indications across Animal Health, Human Health, Diagnostics and Biocomponents.
We aim to transform protein production to allow universal access to biologics.
Single floor facility
Roughly 850m2 including administration, laboratory, rearing and production areas.
Around 1.7kg of recombinant protein/year, equivalent to antigen required to produce up to 100 million vaccine doses (dependent on protein and dose regiment)
GMP certification targeted H2 2021
AREAS OF FOCUS
20 yearsâ€™ experience in the development and production of animal vaccines.
200 molecules successfully produced in collaboration with public and private partners, including multiple international pharmaceutical companies.
First dossier for a veterinary vaccine produced using CrisBio® under review by EMA.
Building on experience in animal health, Algenex is expanding the production of proteins into human health to fully exploit the potential of its technology platformsLearn more
Algenex has an established track record as a producer of antigens proteins for the human and animal diagnostic and therapeutic markets and has also demonstrated the applicability of its technology platform CrisBio® to on-demand production of growth factors, enzymes and cytokines.Learn more
Algenex enters biocomponents market to provide mammalian-fre...
EMA validates Algenexâ€™ CrisBioÂ® platform for the manufacturi...
Call notice for a shareholdersâ€™ meeting of ALTERNATIVE GENE ...